Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE 192.9%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $42M | $32M | $109M | $39M | $59M | $66M | $139M | — | — |
| Enterprise Value | $13M | $3M | $120M | $44M | $67M | $59M | $131M | — | — |
| P/E Ratio → | -1.20 | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.41 | 2.59 | 4.46 | 1.59 | 2.47 | 1.39 | 3.27 | — | — |
| P/B Ratio | 1.57 | 1.15 | — | — | — | 4.87 | 6.69 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.25 | 4.93 | 1.77 | 2.82 | 1.24 | 3.07 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.7% | 53.7% | 43.9% | 44.7% | 48.8% | 40.1% | 48.2% | 46.1% | 40.8% |
| Operating Margin | -149.8% | -149.8% | -146.3% | -123.4% | -147.5% | -48.6% | -31.9% | -19.6% | -21.1% |
| Net Profit Margin | 434.2% | 434.2% | -221.3% | -152.2% | -137.9% | -52.4% | -51.1% | -27.8% | -29.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 192.9% | 192.9% | — | — | -775.1% | -144.6% | -104.8% | — | — |
| ROA | 108.4% | 108.4% | -135.6% | -67.1% | -48.4% | -33.1% | -34.2% | -25.8% | -24.2% |
| ROIC | — | — | — | — | -539.1% | -184.9% | -82.8% | -280.1% | -16.9% |
| ROCE | -103.6% | -103.6% | — | -229.4% | -104.4% | -47.4% | -33.0% | -27.6% | -23.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | — | — | — | 1.72 | 1.47 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | — | — | — | -0.53 | -0.41 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -47.58 | -47.58 | -10.32 | -6.11 | -6.06 | -3.65 | -2.87 | -1.21 | -1.09 |
Net cash position: cash ($36M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.22 | 2.22 | 0.69 | 0.73 | 1.19 | 1.82 | 2.23 | 1.01 | 1.36 |
| Quick Ratio | 2.12 | 2.12 | 0.59 | 0.64 | 1.09 | 1.46 | 1.85 | 0.62 | 0.80 |
| Cash Ratio | 1.45 | 1.45 | 0.35 | 0.45 | 0.40 | 1.17 | 1.46 | 0.14 | 0.18 |
| Asset Turnover | — | 0.20 | 0.67 | 0.57 | 0.35 | 0.71 | 0.52 | 0.96 | 0.82 |
| Inventory Turnover | 2.18 | 2.18 | 3.49 | 3.55 | 2.88 | 2.97 | 2.19 | 3.22 | 3.10 |
| Days Sales Outstanding | — | 195.37 | 105.36 | 87.90 | 269.16 | 46.18 | 61.28 | 61.50 | 67.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.1% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 1.1% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $46M | $29M | $18M | $14M | $10M | $10M | $11M | $11M |
Binary product pipeline dependency
According to recent market data, Elutia trades at a price-to-sales multiple of 3.59, a figure that likely misrepresents the company's underlying growth potential given the significant revenue contraction following the divestiture of its legacy orthobiologics assets and the ongoing transition toward a drug-eluting biologic platform.
The current P/S multiple appears to be an unreliable indicator of value because the denominator is currently depressed by the company's radical portfolio restructuring. Investors should exercise caution when comparing this multiple to peers like LeMaitre Vascular, as Elutia's valuation is currently driven more by the speculative success of its pipeline than by established, recurring revenue streams.
Based on reported financial statements, Elutia's gross margin of 53.66% reflects the inherent cost intensity of porcine-derived tissue processing, which remains significantly lower than the margins typically commanded by synthetic medical device manufacturers in the cardiac protection space.
The deeply negative operating margin of -149.78% suggests that the company's current scale is insufficient to absorb the high fixed costs associated with its specialized manufacturing and clinical sales force. Achieving sustainable profitability will likely require a successful commercial pivot to higher-margin, drug-eluting products to offset the heavy R&D and SG&A burden.
As evidenced by the company's recent financial disclosures, the cash conversion cycle has exhibited extreme volatility, swinging from 179 days in 2023Q4 to -75 days in 2026Q1, which indicates significant instability in inventory management and the collection of receivables from hospital customers.
The erratic nature of these efficiency metrics suggests that the company's supply chain and distribution channels are still adjusting to the post-divestiture business model. Analysts should monitor whether the recent improvement in the cash conversion cycle is a sustainable operational gain or merely a temporary byproduct of inventory liquidation.
According to the most recent quarterly balance sheet, Elutia maintains a current ratio of 2.05, which provides a superficial sense of security, yet this liquidity buffer remains highly vulnerable to the company's persistent operational cash burn and the lack of consistent, positive free cash flow.
While the current ratio has improved from the sub-1.0 levels seen in previous periods, the company's reliance on cash reserves to fund ongoing development suggests that liquidity remains a primary risk factor. Investors should monitor the rate of cash depletion closely, as any delay in product commercialization could necessitate further dilutive financing.
The most commonly misapplied metric for Elutia is the net profit margin, which, at 434.23% in 2025Q4, creates a misleading impression of profitability that ignores the one-time, non-recurring gains derived from the divestiture of the company's orthobiologics business unit.
Using net income to evaluate Elutia's performance obscures the underlying operational reality of a business that is still in the early stages of a high-cost commercial pivot. Analysts should instead focus on cash burn rates and revenue growth from the core CanGaroo platform to gain a more accurate understanding of the company's fundamental health.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELUT stock.
Elutia Inc.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
Elutia Inc.'s return on equity (ROE) is 192.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -18.8%.
Based on historical data, Elutia Inc. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Elutia Inc. has 53.7% gross margin and -149.8% operating margin.